Page 150 - Read Online
P. 150

Maiocchi et al. Vessel Plus 2023;7:27  https://dx.doi.org/10.20517/2574-1209.2023.69  Page 13 of 19

               Table 1. Referent plasma microrna levels in healthy people
                                                    Sample size    Age         Mean normalized concentration
                Abbreviation  Assay ID  Accession number
                                                    n (female, male)  (Avg. ± SEM)  (Avg. ± SEM)
                miR-1      002222   MIMAT0000416    n = 26         37.96 ± 3.18  5.2817 ± 1.4331
                                                    (13, 13)
                miR-133a   002246   MIMAT0000427    n = 20         40.05 ± 3.54  7.7218 ± 3.2159
                                                    (11, 8)
                miR-143    002249   MIMAT0000435    n = 26         39.38 ± 3.37  56.1333 ± 11.0116
                                                    (13, 13)
                miR-145    002149   MIMAT0004601    n = 26         37.96 ± 3.18  2.9591 ± 1.0029
                                                    (13, 13)
                miR-16     000391   MIMAT0000069    n = 26         39.46 ± 3.19  1,786.6109 ± 547.6928
                                                    (13, 13)
                miR-193a   002250   MIMAT0000459    n = 26         37.96 ± 3.18  3.5471 ± 1.2057
                                                    (13, 13)
                miR-21     000397   MIMAT0000076    n = 26         39.03 ± 3.26  332.7083 ± 83.2669
                                                    (13, 13)
                miR-29a    002112   MIMAT0000086    n = 26         39.53 ± 3.34  37.3906 ± 12.4067
                                                    (13, 13)
                miR-30b    000602   MIMAT0000420    n = 26         41.00 ± 2.67  4,895.2872 ± 1,342.2487
                                                    (12, 14)
                miR-574    002349   MIMAT003239     n = 26         40.57 ± 3.24  7.1525 ± 1.5354
                                                    (12, 14)
                miR-147a   000469   MIMAT0000251    n = 25         41.56 ± 3.21  0.2082 ± 0.0646
                                                    (12, 13)
                miR-486    001278   MIMAT0002177    n = 26         40.57 ± 3.24  785.2370 ± 292.3945
                                                    12, 14)
                RNU6B      001973   NR_004394       n = 26         39.43 ± 3.09  53.0385 ± 26.6712
                                                    (11, 15)


               rapidly advance the fields of molecular diagnostics and personalized medicine.


               Each year in the United States, nearly 10,000 people die from aortic aneurysms, and an additional 16,000 die
               from complications associated with aortic disease. Aortic aneurysm is the 17th leading cause of death for
               those over age 65 [11,12] . Discovery most often occurs during evaluation of unrelated problems. This diagnostic
               process is inherently sub-optimal, leaving many undiagnosed and at risk for catastrophic complications
               such as aortic rupture or dissection. During pathological progression, we have demonstrated that miRNAs
                                                                [13]
               are secreted from pathological tissues into the circulation , and levels correlate linearly to aortic diameter
               measurements [3,14] . Moreover, different etiological subtypes generate unique miRNA signatures . Taken
                                                                                                  [3]
               together, this suggests that measuring circulating miRNAs may be used to diagnose, locate, and track aortic
               aneurysm progression in the general population, ultimately informing physicians of optimal timing for
               surgical intervention.

               Standardizing the process of blood draw and use of anticoagulants is crucial for downstream PCR analysis.
               Different anticoagulants can impact the quality and quantity of nucleic acids isolated from blood, affecting
               the accuracy and reliability of PCR results . In this protocol, we demonstrate that EDTA is compatible
                                                    [15]
               with nucleic acid isolation methods and ddPCR assays. Additionally, EDTA is an effective anticoagulant
               that preserves nucleic acids, including miRNAs, by chelating divalent cations necessary for nuclease
               activity . This helps prevent the degradation of nucleic acids during plasma processing. Heparin, however,
                     [16]
                                                             [17]
               should be avoided as it can inhibit PCR amplification . This underlines the importance of standardizing
               blood collection methods. Standardizing blood draw and anticoagulant use ensures a regulated foundation
               on which to proceed and achieve reproducible miRNA quantification.
   145   146   147   148   149   150   151   152   153   154   155